Patti Sparling
Family · Franklin, NCNPI 1720121825
Payments from drug & device makers
Across 656 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$1K
- Novo Nordisk$1K
- Amgen$902
- Lilly USA, LLC$685
- Merck$548
- plus $5K from 32 others
What the payments were for
- Food & beverage$11,49398%
- Education$2302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 150 | $2,887 |
| AstraZeneca | 45 | $1,063 |
| Novo Nordisk | 84 | $1,048 |
| Amgen | 54 | $902 |
| Lilly USA, LLC | 50 | $685 |
| Merck | 34 | $548 |
| GSK | 31 | $541 |
| Pfizer | 25 | $421 |
| Otsuka America Pharmaceutical, Inc. | 16 | $379 |
| Bayer | 17 | $360 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $326 |
| Sanofi-aventis U.S. LLC | 13 | $280 |
| Astellas Pharma US Inc | 9 | $272 |
| Vanda Pharmaceuticals Inc. | 10 | $268 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $249 |
| Novartis | 11 | $159 |
| Boehringer Ingelheim | 8 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $129 |
| Axsome Therapeutics, Inc. | 5 | $124 |
| Exact Sciences | 7 | $110 |
| Amarin Pharma, Inc. | 5 | $106 |
| Corcept Therapeutics | 5 | $87 |
| Viatris Specialty LLC | 4 | $78 |
| Abbott | 4 | $71 |
| Mylan Specialty L.p. | 5 | $71 |
| Biohaven Pharmaceuticals, Inc. | 1 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Lundbeck LLC | 2 | $38 |
| Radius Health, Inc. | 2 | $34 |
| Verona Pharma, Inc. | 2 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Alvogen Inc | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,723 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 78 | $99,070 |
| OzempicSemaglutide | 54 | $88,394 |
| EliquisApixaban | 81 | $87,346 |
| JardianceEmpagliflozin | 66 | $77,725 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $73,070 |
| TrulicityDulaglutide | 44 | $53,466 |
| RexultiBrexpiprazole | 25 | $51,258 |
| ForteoTeriparatide | 11 | $46,103 |
| Repatha SureclickEvolocumab | 38 | $36,296 |
| XareltoRivaroxaban | 36 | $34,383 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $33,173 |
| KerendiaFinerenone | 25 | $32,725 |
| VraylarCariprazine Hcl | 22 | $30,267 |
| MyrbetriqMirabegron | 31 | $28,852 |
| VascepaIcosapent Ethyl | 47 | $28,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Stiolto Respimat | $144 | $136,097139 claims |
| Lilly USA, LLCTrulicity, Forteo, Mounjaro | $685 | $125,38180 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,063 | $115,409104 claims |
| Novo NordiskOzempic | $1,048 | $88,39454 claims |
| PfizerEliquis | $421 | $87,34681 claims |
| GSKTrelegy Ellipta | $541 | $73,07060 claims |
| AbbVieVraylar, Linzess | $2,887 | $58,06641 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $379 | $51,25825 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $280 | $33,17329 claims |
| BayerKerendia | $360 | $32,72525 claims |
| MerckJanuvia, Belsomra | $548 | $32,56745 claims |
| Astellas Pharma US IncMyrbetriq | $272 | $28,85231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Franklin
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.